For the Season 2 finale, we’re at the 2016 annual meeting of the American Society of Hematology (ASH). You’ll hear from Dr Alexis Thompson, Dr Brian Druker, Dr Bruce Cheson and Dr John Leonard on some of the latest developments in hematology.

ASH16 Sand Sculpture on Curing Sickle Cell Disease

Sickle Cell Disease – Interview with Dr Alexis Thompson

Dr Alexis Thompson at ASH16Alexis A Thompson MD MPH is Professor Pediatrics (Hematology, Oncology and Stem Cell Transplantation) at the Northwestern University Feinberg School of Medicine in Chicago. A Vice President of the American Society of Hematology (ASH), she will become President in 2018.

We’ve heard about the promise of cancer immunotherapy and in particular checkpoint inhibitors, but not everyone responds. It’s typically around 25-30% in most cancers.

So how do we identify those patients that are likely to respond, and perhaps more importantly, how can we increase the percentage of patients that do respond?

Immune biomarkers are key to answering both those questions, and understanding the rationale for where we go beyond giving just one checkpoint inhibitor, i.e. monotherapy.

In Ep 2 you’ll hear interviews conducted at the recent American Association of Immunologists (AAI) annual meeting in New Orleans.